Novavax (NVAX)
(Delayed Data from NSDQ)
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
by Zacks Equity Research
Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.
Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.
Company News for Dec 16, 2022
by Zacks Equity Research
Companies in The News Are: NFLX,WBD,NVAX,META
Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.
Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL
by Zacks Equity Research
The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why
by Zacks Equity Research
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI
by Zacks Equity Research
Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook
by Zacks Equity Research
Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -197.29% and 33.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -24.41% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $20.17, marking a -1.61% move from the previous day.
Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $22.81, marking a +1.02% move from the previous day.
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Company News for Oct 21, 2022
by Zacks Equity Research
Companies in The News Are: TSLA, T, ABB, MRNA, NVAX
Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab
by Zacks Equity Research
Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
by Zacks Equity Research
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study
by Zacks Equity Research
Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.